

=====

Sequence Listing could not be accepted.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Thu Jul 26 14:04:13 EDT 2007

=====

Reviewer Comments:

For SEQ ID # 12 through 23, the feature says "Xaa=amino acid." The explanation needs to indicate what amino acids. If the Xaa is "any" amino acid please add the word "any" to the feature.

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: Thu Jul 26 13:41:53 EDT 2007

=====

Reviewer Comments:

For SEQ ID # 12 through 23, the feature says Xaa=amino acid. The explanation needs to indicate what amino acid. If it is "any" amino acid please add the word "any" to the feature.

Application No: 10573576 Version No: 3.0

Input Set:

Output Set:

Started: 2007-07-23 12:38:21.920
Finished: 2007-07-23 12:38:22.082
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 162 ms
Total Warnings: 0
Total Errors: 0
No. of SeqIDs Defined: 30
Actual SeqID Count: 30

SEQUENCE LISTING

<110> THERAPTOSIS S.A.

<120> Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics

<130> 1721-112

<140> 10573576

<141> 2007-07-23

<150> 10/573,576

<151> 2006-03-24

<150> PCT/FR04/02422

<151> 2004-09-24

<150> FR 02 11 270

<151> 2003-09-25

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa=G

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (17)..(17)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (24)..(24)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (26)..(26)

<223> Xaa=G, A, V, L or I

<400> 1

Xaa Xaa Arg Gly Asp Xaa Phe Gly Xaa Xaa Leu Leu Phe Ile His Phe
1 5 10 15

Xaa Ile Gly Ser Xaa His Ser Xaa Ile Xaa

20 25

<210> 2

<211> 28

<212> PRT

<213> Human HIV

<400> 2

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly

20 25

<210> 3

<211> 28

<212> PRT

<213> Human HIV

<400> 3

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly

20 25

<210> 4

<211> 27

<212> PRT

<213> Human HIV

<400> 4

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 5

<211> 28

<212> PRT

<213> Human HIV

<400> 5

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 6

<211> 28

<212> PRT

<213> Human HIV

<400> 6

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 7

<211> 29

<212> PRT

<213> Human HIV

<400> 7

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Asn Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 8

<211> 28

<212> PRT

<213> Human HIV

<400> 8

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 9
<211> 28
<212> PRT
<213> Human HIV

<400> 9
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 10
<211> 28
<212> PRT
<213> Human HIV

<400> 10
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 11
<211> 6
<212> PRT
<213> Human HIV

<400> 11
Arg Gly Asp Met Phe Gly
1 5

<210> 12
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 12
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly

<210> 13
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 13
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

Phe Phe Arg Ile Gly Cys Arg Phe Ser Arg Ile Gly
20 25

<210> 14
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 14
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 15
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>

<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 15
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 16
<211> 27
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 16
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 17
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 17
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 18
<211> 28

<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 18
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 19
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 19
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 20
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 20
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 21

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 21

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 22

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 22

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 23
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 23
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 24
<211> 28
<212> PRT
<213> Human HIV

<400> 24
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 25
<211> 28
<212> PRT
<213> Human HIV

<400> 25
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Ala Ile Gly Ser Arg His Ser Ala Ile Gly
20 25

<210> 26
<211> 27
<212> PRT
<213> Human HIV

<400> 26
Arg Lys Lys Arg Arg Gln Arg Arg Gly Gly Leu Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 27
<211> 16
<212> PRT
<213> Human HIV

<400> 27
Leu Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
1 5 10 15

<210> 28
<211> 12
<212> PRT
<213> Human HIV

<400> 28
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 29
<211> 12

<212> PRT
<213> Human HIV

<400> 29
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 30
<211> 12
<212> PRT
<213> Human HIV

<400> 30
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10

SEQUENCE LISTING

<110> THERAPTOSIS S.A.

<120> Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics

<130> 1721-112

<140> 10573576

<141> 2007-07-23

<150> 10/573,576

<151> 2006-03-24

<150> PCT/FR04/02422

<151> 2004-09-24

<150> FR 02 11 270

<151> 2003-09-25

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa=G

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (17)..(17)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (24)..(24)

<223> Xaa= R or K

<220>

<221> MISC_FEATURE

<222> (26)..(26)

<223> Xaa=G, A, V, L or I

<400> 1

Xaa Xaa Arg Gly Asp Xaa Phe Gly Xaa Xaa Leu Leu Phe Ile His Phe
1 5 10 15

Xaa Ile Gly Ser Xaa His Ser Xaa Ile Xaa

20 25

<210> 2

<211> 28

<212> PRT

<213> Human HIV

<400> 2

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly

20 25

<210> 3

<211> 28

<212> PRT

<213> Human HIV

<400> 3

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly

20 25

<210> 4

<211> 27

<212> PRT

<213> Human HIV

<400> 4
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 5

<211> 28

<212> PRT

<213> Human HIV

<400> 5

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 6

<211> 28

<212> PRT

<213> Human HIV

<400> 6

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 7

<211> 29

<212> PRT

<213> Human HIV

<400> 7

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Asn Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 8

<211> 28

<212> PRT

<213> Human HIV

<400> 8

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 9
<211> 28
<212> PRT
<213> Human HIV

<400> 9
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 10
<211> 28
<212> PRT
<213> Human HIV

<400> 10
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 11
<211> 6
<212> PRT
<213> Human HIV

<400> 11
Arg Gly Asp Met Phe Gly
1 5

<210> 12
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 12
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly

<210> 13
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 13
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

Phe Phe Arg Ile Gly Cys Arg Phe Ser Arg Ile Gly
20 25

<210> 14
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 14
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 15
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>

<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 15
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 16
<211> 27
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 16
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 17
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 17
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 18
<211> 28

<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 18
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 19
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 19
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 20
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 20
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 21

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 21

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 22

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 22

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 23
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 23
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 24
<211> 28
<212> PRT
<213> Human HIV

<400> 24
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 25
<211> 28
<212> PRT
<213> Human HIV

<400> 25
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Ala Ile Gly Ser Arg His Ser Ala Ile Gly
20 25

<210> 26
<211> 27
<212> PRT
<213> Human HIV

<400> 26
Arg Lys Lys Arg Arg Gln Arg Arg Gly Gly Leu Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 27
<211> 16
<212> PRT
<213> Human HIV

<400> 27
Leu Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
1 5 10 15

<210> 28
<211> 12
<212> PRT
<213> Human HIV

<400> 28
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 29
<211> 12

<212> PRT
<213> Human HIV

<400> 29
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 30
<211> 12
<212> PRT
<213> Human HIV

<400> 30
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10